Fears over vaccines block

Share this article:
The weekly Cancer Letter says recent Capitol Hill testimony by the acting director of the National Cancer Institute (NCI) suggests that human papilloma virus (HPV) vaccines, objected to by the religious right, might have approval blocked by the FDA. Both Merck and GlaxoSmithKline are developing 
vaccines.

According to the Cancer Letter, NCI acting director John Niederhuber seemed to downplay the vaccines' importance for US women, notwithstanding one's success in an NCI-sponsored trial, when he appeared before the House Appropriations Subcommittee on Labor, HHS and Education.

However, in the third world, Niederhuber said, “the impact of this could be just absolutely huge.” The Cancer Letter says social conservatives are expected to oppose HPV vaccines at FDA the same way they opposed the emergency contraceptive Plan B.

The letter goes on to  quote Reproductive Health Technologies Project president Kirsten Moore as saying Niederhuber's testimony sounded “like the birth of a convenient excuse not to look at what HPV vaccines could do for this country.”

Some religious right advocates claim that HPV vaccines, like Plan B, would encourage sexual promiscuity, especially among the young.
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.